Immune-Related Meningoencephalitis following Nivolumab in Metastatic Renal Cell Carcinoma
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
Immune-Related Meningoencephalitis following Nivolumab in Metastatic Renal Cell Carcinoma ; volume:14 ; number:2 ; year:2021 ; pages:1051-1058 ; extent:8
Case reports in oncology ; 14, Heft 2 (2021), 1051-1058 (gesamt 8)
- Urheber
-
Shields, Lisa B.E.
Alsorogi, Mohammad S.
Mar, Nataliya
Rezazadeh Kalebasty, Arash
- DOI
-
10.1159/000513001
- URN
-
urn:nbn:de:101:1-2021090900432729608396
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
- 15.08.2025, 07:21 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Shields, Lisa B.E.
- Alsorogi, Mohammad S.
- Mar, Nataliya
- Rezazadeh Kalebasty, Arash
Ähnliche Objekte (12)
Myocarditis as an immune-related adverse event following treatment with ipilimumab and nivolumab combination therapy for metastatic renal cell carcinoma: a case report
Calcitriol-mediated hypercalcemia as an immune-related adverse event in a patient receiving nivolumab and ipilimumab for metastatic renal cell carcinoma, case report
Renal Immune-Related Adverse Event Difficult to Diagnose during Nivolumab Treatment for Hypopharyngeal Carcinoma: Case Report
Immunomodulatory response to neoadjuvant nivolumab in non-metastatic clear cell renal cell carcinoma
Nivolumab induced encephalopathy in a man with metastatic renal cell cancer: a case report
Nivolumab for Metastatic Cutaneous Squamous Cell Carcinoma
Metastatic Merkel cell carcinoma response to nivolumab
Immune-related hepatitis in a patient with hepatocellular carcinoma treated with nivolumab
Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program
Pre-treatment metastatic growth rate is associated with clinical outcome in patients with metastatic renal cell carcinoma treated with nivolumab
Prognostic impact of FAN score in patients receiving nivolumab plus ipilimumab for metastatic renal cell carcinoma
Visceral Leishmaniasis in a 62-Year-Old Woman with Metastatic Renal Cancer in Treatment with Nivolumab
Myocarditis as an immune-related adverse event following treatment with ipilimumab and nivolumab combination therapy for metastatic renal cell carcinoma: a case report
Calcitriol-mediated hypercalcemia as an immune-related adverse event in a patient receiving nivolumab and ipilimumab for metastatic renal cell carcinoma, case report
Renal Immune-Related Adverse Event Difficult to Diagnose during Nivolumab Treatment for Hypopharyngeal Carcinoma: Case Report
Immunomodulatory response to neoadjuvant nivolumab in non-metastatic clear cell renal cell carcinoma
Nivolumab induced encephalopathy in a man with metastatic renal cell cancer: a case report
Nivolumab for Metastatic Cutaneous Squamous Cell Carcinoma
Metastatic Merkel cell carcinoma response to nivolumab
Immune-related hepatitis in a patient with hepatocellular carcinoma treated with nivolumab
Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program
Pre-treatment metastatic growth rate is associated with clinical outcome in patients with metastatic renal cell carcinoma treated with nivolumab
Prognostic impact of FAN score in patients receiving nivolumab plus ipilimumab for metastatic renal cell carcinoma
Visceral Leishmaniasis in a 62-Year-Old Woman with Metastatic Renal Cancer in Treatment with Nivolumab
Myocarditis as an immune-related adverse event following treatment with ipilimumab and nivolumab combination therapy for metastatic renal cell carcinoma: a case report
Calcitriol-mediated hypercalcemia as an immune-related adverse event in a patient receiving nivolumab and ipilimumab for metastatic renal cell carcinoma, case report
Renal Immune-Related Adverse Event Difficult to Diagnose during Nivolumab Treatment for Hypopharyngeal Carcinoma: Case Report
Immunomodulatory response to neoadjuvant nivolumab in non-metastatic clear cell renal cell carcinoma
Nivolumab induced encephalopathy in a man with metastatic renal cell cancer: a case report
Nivolumab for Metastatic Cutaneous Squamous Cell Carcinoma
Metastatic Merkel cell carcinoma response to nivolumab
Immune-related hepatitis in a patient with hepatocellular carcinoma treated with nivolumab
Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program
Pre-treatment metastatic growth rate is associated with clinical outcome in patients with metastatic renal cell carcinoma treated with nivolumab
Prognostic impact of FAN score in patients receiving nivolumab plus ipilimumab for metastatic renal cell carcinoma